HTEC

INVESTING IN HEALTHCARE TECHNOLOGY & INNOVATION

HEALTHCARE APPEARS TO BE AT THE VERY BEGINNING OF A TECHNOLOGY-DRIVEN REVOLUTION.

The convergence of robotics, machine intelligence, and life sciences is enabling breakthrough advancements that touch almost every aspect of healthcare. While the list of innovations is vast, these technologies are still in their earliest stages.



We believe this technology revolution will profoundly transform the healthcare industry. Innovation is expected to create profit opportunities for some businesses, while commoditization will reduce margins for others, and even render some obsolete. In our opinion the emerging winners of this disruption will be those companies that are able to effectively deploy innovations such as genomics, precision medicine, or robotics, automation, and AI (RAAI) to improve the quality of care while reducing costs.

This disruption is driving a compelling yet complex investment opportunity. There are an increasing number of entrants and partnerships worldwide that are seeking to facilitate a more modernized approach to medicine. This seems to be a testament to the growth opportunity, but it also bears an overwhelming web of options and investment ideas. To simplify this, ROBO Global has partnered with Exchange Traded Concepts to offer a liquid, transparent, and cost-effective ETF to provide investors with access to this transformative yet complex theme.

- **AI-powered diagnostics**
- **Minimally invasive robotic surgery**
- **Lab automation**
- **DNA sequencing**
- **Genetic cancer therapies**
- **3D-printed implants and organs**
- **Wearable medical devices**
- **Virtual care visits**

GLOBAL UNMET NEEDS ARE DRIVING HEALTHCARE INNOVATION

Although healthcare is already a globally mature industry (~$10 trillion, or 10.3% of world GDP as of 2023) [1], expenditure is rising unsustainably, in the US alone, healthcare spending accounted for over $4 trillion in 2022, and going forward is expected to outpace GDP growth [2]. Efforts to lower costs of care and to improve the well-being of people are creating a necessity for innovation. The ROBO Global Healthcare Technology & Innovation Index seeks to capture the value created by the possible ensuing breakthroughs.

We view the following as key trends that should drive industry growth:

The first step is admitting there is a problem. Healthcare today is designed to treat people who are already sick. Society is acknowledging a significant savings opportunity in lowering chronic disease incidence, which is causing a shift in focus from "sick care" toward preventative care. Providers and insurance companies alike are seeking to keep an eye on their patients throughout the year, rather than the occasional doctor's visit. Companies that provide AI, remote patient monitoring, and modernized diagnostics are among those who are well-positioned for this trend.

The robot will see you now. A wide range of automation and robotics technologies are being offered throughout the healthcare ecosystem, from hospital to pharmacy to home, to improve patient safety and physicians' accuracy and productivity, while addressing the growing provider shortage.

What works for some may not work for others. The one-size-fits-all methodology that is the standard of care in medicine can be ineffective, even dangerous, for many patients currently undergoing treatment. Advancements in genomic science, precision medicine, and advanced data analytics are enabling the medical community to tailor treatments for every individual.

The time for change is now. Lowering costs in healthcare has become an imperative. The system is littered with burdensome administrative tasks and overhead. The introduction of Artificial Intelligence as well as other advancements in healthcare technology are driving rapid — and much needed — change to foster improved patient and provider environments.

Most importantly for investors and society, it's early days for these advancements, and we believe the greatest gains from healthcare technology and innovation lie ahead. We anticipate a long runway for global adoption and penetration for robot-augmented surgery, early- diagnostic tools, minimally invasive treatments, telehealth, and many more applications.

These improvements in healthcare technology have the potential to disrupt many existing business models and could create high-growth new markets for the most innovative healthcare companies. The ROBO Global Healthcare Technology & Innovation Index is designed to identify and invest in the equity of technology and market leaders driving this revolution around the world.

1 WHO - https://www.who.int/news/item/11-12-2023-who-calls-on-governments-for-urgent-action-to-invest-in-universal-health-coverage
2 CMS - https://www.cms.gov/data-research/statistics-trends-and-reports/national-health-expenditure-data/nhe-fact-sheet

HTEC
INVESTING IN HEALTHCARE TECHNOLOGY & INNOVATION

ROBO GLOBAL®

ROBO Global's Industry Classification is a forward-looking road map, supported by insights from a dedicated coverage team, to ensure subsectors evolve and expand at the right time.



For investors seeking a way to capture the entire value chain of healthcare technology and innovation, these are the details that matter. At ROBO Global, we strive to deliver a research-driven portfolio, focused on providing long-term growth. Investors would be wise to consider using the HTEC ETF as a means to gain diversified exposure to this innovation.

PRODUCT INFORMATION CHART:

Fund Name:	**ROBO Global Healthcare Technology & Innovation ETF**
Benchmark:	**ROBO Global Healthcare Technology & Innovation Index**
Ticker:	**HTEC**
Listings:	**NYSE Arca**
Fund Inception Date:	**06/25/2019**
Expense Ratio:	**0.80% (Gross) / 0.68% (Net)***
Issuer:	**Exchange Traded Concepts**

**The Advisor has contractually agreed to waive fees through August 31, 2025*

LEARN MORE

To learn more about the ROBO Global Healthcare Technology & Innovation ETF, visit www.roboglobaletfs.com.

IMPORTANT DISCLOSURES

This material represents the author's assessment of the market environment at a specific time and is not intended to be a forecast of future events or a guarantee of future results. This information should not be relied upon by the reader as research or investment advice regarding the fund or any security in particular. Please consult your financial advisor for further information.

Diversification may not protect against market risk. Investing involves risk, including the possible loss of principal. Narrowly focused investments and investments in smaller companies typically exhibit higher volatility. International investments may also involve risk from unfavorable fluctuations in currency values, differences in generally accepted accounting principles, and from economic or political instability. Emerging markets involve heightened risks related to the same factors as well as increased volatility and lower trading volume. Indices are unmanaged. One cannot invest directly in an index. There is no guarantee the fund will achieve its stated objective. Holdings are subject to change. Current and future holdings are subject to risk.

The Fund invests primarily in the equity securities of Medical Technology Companies and, as such, is particularly sensitive to risks to those types of companies. These risks include, but are not limited to, small or limited markets for such securities, changes in business cycles, world economic growth, technological progress, rapid obsolescence, and government regulation.

Carefully consider the Fund's investment objectives, risk factors, charges and expenses before investing. This and additional information can be found in the Fund's full or summary prospectus, which may be obtained at www.roboglobaletfs.com. Read the prospectus carefully before investing.

This information is not intended to be individual or personalized investment or tax advice and should not be used for trading purposes.

Exchange Traded Concepts, LLC serves as the investment advisor of the fund. The Fund is distributed by SEI Investments Distribution Co. (SIDCO), which is not affiliated with Exchange Traded Concepts, LLC or any of its affiliates.

Shares are bought and sold at market price (closing price) not net asset value (NAV) and are not individually redeemed from the Fund. Beginning September 1, 2020, market price returns are based on the official closing price of an ETF share or, if the official closing price isn't available, the midpoint between the national best bid and national best offer ("NBBO") as of the time the ETF calculates current NAV per share. Prior to September 1, 2020, market price returns were based on the midpoint between the bid and ask price